A newly developed blood test that measures the body's T cell immune response to SARS-CoV-2 could give individuals "a comprehensive picture" of their immune protection against the virus, Denise Chow reports for NBC News.
Many hospital websites have installed a tracking tool that collects users' potentially sensitive health information and sends it to Facebook—a situation that health data security experts say may be a violation of HIPAA regulations, Todd Feathers, Simon Fondrie-Teitler, Angie Waller, and Surya Mattu write for The Markup/STAT+.
A study finds relatively few high-risk patients experience "viral rebound" after taking Paxlovid, FDA's potential authorization of Novavax's Covid-19 vaccine is delayed until the agency can fully review the company's manufacturing process, and more in this week's roundup of Covid-19 news.
Roche on Thursday announced the disappointing trial results of its Alzheimer's drug crenezumab—but some experts say "[t]his is by no means the end of the story."
The Supreme Court on Wednesday unanimously ruled that reimbursement rate cuts under the 340B drug discount program were "unlawful"—marking what stakeholders describe as a "decisive victory for vulnerable communities and the hospitals on which so many patients depend." But Advisory Board researchers Chloe Bakst, Lindsey Paul, and Gina Lohr remain concerned about the future of the 340B program for two key reasons.
CVS Health named Violetta Ostafin EVP and chief strategy officer, effective July 11, in today's bite-sized hospital and health industry news from California, Rhode Island, and Texas.
